335 related articles for article (PubMed ID: 11133748)
21. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.
Colombat P; Brousse N; Salles G; Morschhauser F; Brice P; Soubeyran P; Delwail V; Deconinck E; Haioun C; Foussard C; Sebban C; Tilly H; Thieblemont C; Bergougnoux L; Lazreg F; Solal-Celigny P
Ann Oncol; 2012 Sep; 23(9):2380-2385. PubMed ID: 22782332
[TBL] [Abstract][Full Text] [Related]
22. [Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma].
Belada D; Smolej L; Stepánková P; Beránek M; Dvoráková D; Bukac J; Malý J
Vnitr Lek; 2007 Oct; 53(10):1057-63. PubMed ID: 18072430
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
24. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
25. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
Maloney DG; Grillo-López AJ; White CA; Bodkin D; Schilder RJ; Neidhart JA; Janakiraman N; Foon KA; Liles TM; Dallaire BK; Wey K; Royston I; Davis T; Levy R
Blood; 1997 Sep; 90(6):2188-95. PubMed ID: 9310469
[TBL] [Abstract][Full Text] [Related]
26. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C
Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924
[TBL] [Abstract][Full Text] [Related]
27. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
28. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
Kennedy GA; Blum R; McCormack C; Prince HM
Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
[TBL] [Abstract][Full Text] [Related]
29. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Jäger U; Fridrik M; Zeitlinger M; Heintel D; Hopfinger G; Burgstaller S; Mannhalter C; Oberaigner W; Porpaczy E; Skrabs C; Einberger C; Drach J; Raderer M; Gaiger A; Putman M; Greil R;
Haematologica; 2012 Sep; 97(9):1431-8. PubMed ID: 22511498
[TBL] [Abstract][Full Text] [Related]
30. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
McLaughlin P; Grillo-López AJ; Link BK; Levy R; Czuczman MS; Williams ME; Heyman MR; Bence-Bruckler I; White CA; Cabanillas F; Jain V; Ho AD; Lister J; Wey K; Shen D; Dallaire BK
J Clin Oncol; 1998 Aug; 16(8):2825-33. PubMed ID: 9704735
[TBL] [Abstract][Full Text] [Related]
31. Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma.
Avilés A; Talavera A; Díaz-Maqueo JC; García EL; Cleto S; Neri N
Cancer Biother Radiopharm; 2001 Apr; 16(2):159-62. PubMed ID: 11385962
[TBL] [Abstract][Full Text] [Related]
32. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.
van Oers MH; Klasa R; Marcus RE; Wolf M; Kimby E; Gascoyne RD; Jack A; Van't Veer M; Vranovsky A; Holte H; van Glabbeke M; Teodorovic I; Rozewicz C; Hagenbeek A
Blood; 2006 Nov; 108(10):3295-301. PubMed ID: 16873669
[TBL] [Abstract][Full Text] [Related]
33. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
34. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
35. Prolonged remission in a patient with relapsed follicular lymphoma after a single course of rituximab.
Jensen M; Elter T; Engert A; Reiser M
Onkologie; 2006 Mar; 29(3):90-2. PubMed ID: 16514269
[TBL] [Abstract][Full Text] [Related]
36. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
[TBL] [Abstract][Full Text] [Related]
37. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
38. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
39. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
Ghielmini M; Schmitz SF; Cogliatti SB; Pichert G; Hummerjohann J; Waltzer U; Fey MF; Betticher DC; Martinelli G; Peccatori F; Hess U; Zucca E; Stupp R; Kovacsovics T; Helg C; Lohri A; Bargetzi M; Vorobiof D; Cerny T
Blood; 2004 Jun; 103(12):4416-23. PubMed ID: 14976046
[TBL] [Abstract][Full Text] [Related]
40. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
